title: In vitro and in vivo antimalarial activities of T-2307, a novel arylamidine.
abstract: T-2307, a novel arylamidine, has been shown to exhibit broad-spectrum antifungal activities against clinically significant pathogens. Here, we evaluated the in vitro and in vivo antimalarial activity of T-2307. The 50% inhibitory concentrations (IC₅₀s) of T-2307 against Plasmodium falciparum FCR-3 and K-1 strains were 0.47 and 0.17 μM, respectively. T-2307 at 2.5 to 10 mg/kg of body weight/day exhibited activity against blood stage and liver stage parasites in rodent malaria models. In conclusion, T-2307 exhibited in vitro and in vivo antimalarial activity.
authors.affiliation: Research Laboratories, Toyama Chemical Co., Ltd., Toyama, Japan. akiko_kimura@toyama-chemical.co.jp
authors.forename: Akiko
authors.initials: A
authors.lastname: Kimura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nishikawa
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Nomura
authors.forename: Junichi
authors.initials: J
authors.lastname: Mitsuyama
authors.forename: Shinya
authors.initials: S
authors.lastname: Fukumoto
authors.forename: Noboru
authors.initials: N
authors.lastname: Inoue
authors.forename: Shin-Ichiro
authors.initials: S
authors.lastname: Kawazu
mesh_terms: D000578:Amidines / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D000962:Antimalarials / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D020128:Inhibitory Concentration 50; D008099:Liver / Q000469:parasitology; D008288:Malaria / Q000188:drug therapy* / Q000469:parasitology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D059208:Parasite Load; D010962:Plasmodium berghei / Q000187:drug effects; D016788:Plasmodium chabaudi / Q000187:drug effects; D010963:Plasmodium falciparum / Q000187:drug effects* / Q000648:ultrastructure
chemical_list: D000578:Amidines; D000962:Antimalarials; C573060:T-2307